Hypertension
Conference Coverage
Dietary change tops for reducing CVD risk in stage 1 hypertension
Healthy lifestyle changes, particularly adoption of the DASH diet, can reduce CVD events in people with stage 1 hypertension.
From the Journals
Lack of exercise linked to small heart, HFpEF
Chronic “exercise deficiency” is a major risk factor for heart failure with preserved ejection fraction, and regular physical activity ... may...
Feature
‘Spectacular’ polypill results also puzzle docs
“If they got the same results on the biomarkers that the pill was designed to intervene upon, why are the [primary outcome] results different? It’...
Feature
How does salt intake relate to mortality?
Although there is an ongoing debate about the extent of salt’s effects ... there is no doubt that in most places in the world, people are...
From the Journals
Artificial sweeteners linked to higher CV event risk
The first study to include artificial sweetener from all sources, not just drinks, may increase concerns about these agents. But not all are...
Latest News
Candy, desserts: A ‘gateway’ to unhealthy eating among teens
Over the past 30 years, there’s been a steady increase in consumption of ultra-processed foods worldwide, coupled with mounting evidence that...
Conference Coverage
COVID-19 vaccine safe in patients with heart failure
There should be no concern about cardiovascular side effects from mRNA vaccines in patients with HF; moreover, vaccines provide a survival benefit...
Conference Coverage
AXIOMATIC-SSP: Cautious optimism on factor XI inhibitor in stroke
The new factor XI inhibitor antithrombotic, milvexian, showed promising results in a dose-finding phase 2 trial in patients with acute ischemic...
Conference Coverage
Artificial intelligence poised to change paradigm of CV risk prevention
A new generation causal-based AI algorithm promises to personalize CV risk management to prevent events.
Conference Coverage
DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening
Comprehensive cardiovascular screening fell short of significantly reducing all-cause mortality in men aged 65-74, but some benefits were seen.
Conference Coverage
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction–agnostic...